Page last updated: 2024-09-04

irofulven and Peritoneal Carcinomatosis

irofulven has been researched along with Peritoneal Carcinomatosis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP1

Trials

1 trial(s) available for irofulven and Peritoneal Carcinomatosis

ArticleYear
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome

2010